Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis
about
Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosisMolecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2.Progress in matrix metalloproteinase research.High matrix metalloproteinase production correlates with immune activation and leukocyte migration in leprosy reactional lesions.Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitisPromoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma.Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus.Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration.Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancerDeficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient miceMatrix metalloproteinase-9 in lung remodeling.Epigenetic silencing of TFPI-2 in canine diffuse large B-cell lymphomaDecreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinomaCorrelation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinomaEffects of ectopic Nanog and Oct4 overexpression on mesenchymal stem cellsFibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata.Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer.Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach.Upregulated matrix metalloproteinase-2 and downregulated tissue factor pathway inhibitor-2 are risk factors for lymph node metastasis and perineural invasion in pancreatic carcinoma.Urinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression.Tissue Factor Pathway Inhibitor-2 Gene Polymorphisms Associate With Coronary Atherosclerosis in Chinese Population.Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.Targeting matrix metalloproteases to improve cutaneous wound healing.Increased matrix metalloproteinase-2 expression and reduced tissue factor pathway inhibitor-2 expression correlate with angiogenesis and early postoperative recurrence of pancreatic carcinoma.Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular diseaseMatrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted.Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability.Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer.Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathyTargeting TFPI for hemophilia treatment.Human tissue factor pathway inhibitor-2 is internalized by cells and translocated to the nucleus by the importin system.Atrial extracellular matrix remodelling in patients with atrial fibrillation.Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells.Vascular smooth muscle cell in atherosclerosis.Induction of Tissue Factor Pathway Inhibitor 2 by hCG Regulates Periovulatory Gene Expression and Plasmin Activity.Adenovirus-mediated gene transfer of tissue factor pathway inhibitor-2 inhibits gallbladder carcinoma growth in vitro and in vivo.CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion.
P2860
Q24681706-CF81C577-A00E-42CE-ACED-31D9093E7ED6Q30440977-6550C34C-4E47-44EA-9433-FF8A0D11DFE7Q33241217-EBF8A251-46B8-46F9-9055-0F30FD1CF081Q33608536-6C54E81C-278B-4874-830C-DC7A8CD99E60Q33675870-B3721703-2F7D-4B5B-98D5-B3137E4C1CA8Q33780202-1808792C-ECB7-4349-B762-77AEFA2E094CQ34161719-652ECE4B-D62F-46EF-8C96-50CB5F740CBCQ34222704-76B81898-BE97-4C3A-8EF3-EB297666C018Q34592412-D28D40EA-5B45-4F5E-828E-EAD7A554E9FFQ34623032-62FA3F25-F721-4691-BC9A-B964959B2DFFQ34967612-066D8A58-EC6B-41A7-935B-8271771741D3Q35032152-82659D42-E9E1-44BA-A43B-288CB6CF407FQ35138335-7CA9CECA-B874-4FCF-8B32-0C7887B044BEQ35144899-378FBA01-74B1-49B4-B82C-5B5CD5AA2A12Q35145167-BEE5A4C7-0BE4-4FB6-A461-8C257E4E17F6Q35304774-34524916-B726-4CF2-9AEA-6A7D232768DDQ35492880-05CB3E3D-5083-42AC-A2A8-72C575343302Q35858377-E12AF231-879F-48E0-8FF6-BD8C5056E365Q36009930-4147CDFD-B16F-4E9C-95A8-57922A2AC054Q36066182-3D718F7A-91E8-4FEA-9C52-F26B78EB7578Q36156149-311D1F37-266F-409E-9BB1-B729865042EBQ36206158-1840D307-7209-4AF2-BE7A-C1A84A54CC71Q36207118-3DAF2A7A-9388-47A9-ABA4-EC71573C1771Q36316444-C11646AB-55E4-4C02-AD10-03AEFFC67515Q36379390-E4A2809D-8FE3-4500-AB42-B8DB4D26900DQ36420282-681FB7DB-28FC-4CDA-BDCA-151A3FDB4CF4Q36477722-0C9C394D-2F24-4F7A-8373-83131EF054E7Q36644577-145492B8-F508-429B-A8B8-A0A1A81CA491Q36712749-217910C9-3A49-424A-8F93-E38A8C2EDA68Q36752100-95ABD6ED-B32B-4199-A641-699870E69660Q37043566-411D558B-C713-49A2-99F6-1DBAEA414560Q37069135-CC755E15-E896-42E8-A3D8-8A07B5920F44Q37108074-A4D27DC3-0AB9-43B7-8441-0EE0AA52E46AQ37152354-7A5DC3A8-0B20-46EE-87CD-9B4EFA87B9FDQ37296366-B9C8F654-C426-4940-8E04-884573C9717AQ38350779-64D40743-4615-4862-A1B7-987F2AB35155Q38353932-1C7FB38E-6626-4B40-953E-9FFD2A668B44Q39215224-8FF70104-318C-4337-8F0F-BCB6347C4F8BQ39399156-8EF6F59B-58EF-4081-B82C-AAC192F23250Q39460924-9C3842EB-D809-41B2-99CE-61AD99918C94
P2860
Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Tissue factor pathway inhibito ...... plications for atherosclerosis
@ast
Tissue factor pathway inhibito ...... plications for atherosclerosis
@en
Tissue factor pathway inhibito ...... plications for atherosclerosis
@nl
type
label
Tissue factor pathway inhibito ...... plications for atherosclerosis
@ast
Tissue factor pathway inhibito ...... plications for atherosclerosis
@en
Tissue factor pathway inhibito ...... plications for atherosclerosis
@nl
prefLabel
Tissue factor pathway inhibito ...... plications for atherosclerosis
@ast
Tissue factor pathway inhibito ...... plications for atherosclerosis
@en
Tissue factor pathway inhibito ...... plications for atherosclerosis
@nl
P2093
P2860
P356
P1476
Tissue factor pathway inhibito ...... plications for atherosclerosis
@en
P2093
G K Sukhova
M P Herman
U Schönbeck
P2860
P304
P356
10.1172/JCI10403
P407
P577
2001-05-01T00:00:00Z